Evidence map›Paper›PMID 31429779›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.

Apostolos Zaravinos, Constantinos Roufas, Majdi Nagara, Beatriz de Lucas Moreno, Maria Oblovatskaya, Christodoulos Efstathiades, Christos Dimopoulos, Georgios D Ayiomamitis

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 106 citations in OpenAlex.

  1. Trial
  2. Article
  3. Revealing the dynamics of follicular T cells and checkpoint engagement in surgically resected colorectal cancer and their relations to clinicopathological aspects.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Immune Cytolytic Activity and Strategies for Therapeutic Treatment.International journal of molecular sciences · 2024
    Review
  14. New insight in immunotherapy and combine therapy in colorectal cancer.Frontiers in cell and developmental biology · 2024
    Review
  15. Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer.Journal of gastrointestinal cancer · 2023
    Review
  16. Review
  17. Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023
    Article
  18. Article
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 4 countries.

Apostolos ZaravinosDepartment of Life Sciences, School of Sciences, European University Cyprus, 1516, Nicosia, Cyprus. A.Zaravinos@euc.ac.cy.ORCID http://orcid.org/0000-0003-4625-5562
Constantinos RoufasDepartment of Life Sciences, School of Sciences, European University Cyprus, 1516, Nicosia, Cyprus.
Majdi NagaraInserm, UMR-S 1251, MMG, Faculté de Médecine, Aix Marseille University, Marseille, France.
Beatriz de Lucas MorenoDepartment of Life Sciences, School of Sciences, European University Cyprus, 1516, Nicosia, Cyprus.
Maria OblovatskayaDepartment of Life Sciences, School of Sciences, European University Cyprus, 1516, Nicosia, Cyprus.
Christodoulos EfstathiadesCentre for Risk and Decision Sciences (CERIDES), 2404, Nicosia, Cyprus.
Christos DimopoulosCentre for Risk and Decision Sciences (CERIDES), 2404, Nicosia, Cyprus.
Georgios D Ayiomamitis1st Surgical Department, Tzaneion General Hospital, 18536, Piraeus, Greece.
European University Cyprus · CYInserm · FRTzaneion General Hospital · GR

Funding

Cyprus Research Promotion Foundation ENTERPRISES/0916/0083
6 · The paper itself

Abstract

backgroundMicrosatellite unstable colorectal cancers (MSI+ CRCs) expressing PD-L1, respond to anti-PD-1 or anti-PD-L1 checkpoint blockade, whereas microsatellite-stable tumors do not respond the same. Our aim was to examine how the immune landscape relates to different aspects of the CRC's biology, including neoepitope burden.

methodsWe used TCGA data to stratify patients based on a cytolytic T-cell activity expression index and correlated immune cytolytic activity (CYT) with mutational, structural, and neoepitope features of each tumor sample. The expression of several immune checkpoints was verified in an independent cohort of 72 CRC patients, relative to their MSI status, using immunohistochemistry and RT-qPCR.

resultsCRC exhibits a range of intertumoral cytolytic T-cell activity, with lower cytolytic levels in the tumor, compared to the normal tissue. We separated CRC patients into CYT-high and CYT-low subgroups. High cytolytic activity correlated with increased mutational load in colon tumors, the count of MHC-I/-II classically defined and alternatively defined neoepitopes, high microsatellite instability and deregulated expression of several inhibitory immune checkpoints (VISTA, TIGIT, PD-1, IDO1, CTLA-4, and PD-L1, among others). Many immune checkpoint molecules (IDO1, LAG3, TIGIT, VISTA, PD-1, PD-L1 and CTLA-4) expressed significantly higher in MSI+ CRCs compared to MSS tumors. The expression of Treg markers was also significantly higher in CYT-high tumors. Both individual and simultaneous high levels of CTLA-4 and PD-L1 had a positive effect on the patients' overall survival. On the reverse, simultaneous low expression of both genes led to a significant shift towards negative effect. Assessed globally, CYT-low CRCs contained more recurrent somatic copy number alterations. PD-L1 protein was absent in most samples in the independent cohort and stained lowly in 33% of MSI CRCs. PD-L1+ CRCs stained moderately for CD8 and weakly for FOXP3. CYT-high colon tumors had higher TIL load, whereas CYT-high rectum tumors had higher TAN load compared to their CYT-low counterparts.

conclusionsOverall, we highlight the link between different genetic events and the immune microenvironment in CRC, taking into consideration the status of microsatellite instability. Our data provide further evidence that MSI+ and CYT-high tumors are better candidates for combinatorial checkpoint inhibition.

Indexed as

Microsatellite InstabilityMutationB7-H1 AntigenBiomarkers, TumorCohort StudiesColorectal NeoplasmsCTLA-4 AntigenFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingPrognosisT-Lymphocytes, CytotoxicB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humanAlternatively defined neoepitopesCancer driversClassically defined neoepitopesColorectal cancerCytolytic activityImmune checkpointsMutation burden

Identifiers

PMID31429779
PMCPMC6701076
OpenAlexW2969887486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.